---
title: "Amarin Corporation plc"
url: https://duttonassociates.com/research/AMRN/
description: "Company profile for Amarin Corporation plc (AMRN) as published by Dutton Associates, with company facts and the firm's published research on the company."
---

# Amarin Corporation plc

AMRN

Nasdaq

7 Curzon Street
London , W1J 5HG
Phone: (415) 389-4920

Amarin Corporation is a specialty pharmaceutical company focused on neurology. Amarin is listed on NASDAQ (ticker: AMRN) and has its headquarters in London. Amarin currently employs over 100 people and achieved record revenues of $65.4mn in 2002. Amarin operates through two main subsidiaries:

Amarin Pharmaceuticals Inc. based in San Francisco, is focused on the sales and marketing of Amarin's US product portfolio utilizing a specialty neurology sales force.

Amarin Development AB, based in Malmo, Sweden, is dedicated to advanced product development and reformulation using oral and site-specific drug delivery solutions.

Amarin's leading product is Permax®, a dopamine agonist, used in the treatment of Parkinson's disease. In addition, Amarin owns a portfolio of primary care products which includes treatments for tension headache, obesity and diarrhea.

Amarin's product development pipeline includes Zelapar™ for Parkinson's disease, for which an approvable letter has been received from the Food and Drug Administration (FDA) in the US, and LAX-101 for Huntington's Disease, currently in Phase III clinical trials in the US.

## Company Facts

**Symbol**: AMRN

**Exchange**: Nasdaq

**Equity Data**: (as of 6/30/03)

**Shares Outstanding**: 17.9 million

**Recent Trading Price**: $ 2.98 (09/22/2003)

**J.M. Dutton Analyst**: Stephen L. Handley

**Current rating**: Speculative Buy

**Price target**: $4.50

**Rating established**: 09/22/2003

www.amarincorp.com

[Back to the coverage register](https://duttonassociates.com/research/)

[Rating schedule](https://duttonassociates.com/Ratings/Ratings.html)

## Published Research

- 10/29/2003Research noteAmarin Accomplishes Important Sale of its Swedish Drug Development Subsidiary For $15 Million
- 09/22/2003Research reportAmarin Speculative Buy Rating Issued In Initiating Coverage